Design and Synthesis of New Quinazoline Hybrid Molecules as EGFR Targeting Anti-Breast Cancer Agents

Abstract

In the present work, we described the synthesis of some quinazoline-1,2,3-triazole hybrids (5a-o) and their structures were analysed by ¹H NMR, ¹³C NMR and Mass spectral analysis. These hybrids were further screened for their in vitro anti-breast cancer activity against two human breast cancer cell lines which includes MCF-7 and MDA-MB-231. The results indicated that compounds 5d and 5e showed more activity than the standard drug 5-fluorouracil (5-FU) against two breast cancer cell lines. Also, compound 5b has shown almost similar activity against two cancer cell lines to the positive control. Further, compound 5e showed comparable inhibition against tyrosine kinase EGFR to the standard drug erlotinib. Furthermore, molecular docking studies exposed the important binding interactions of compounds 5b, 5d and 5e with the EGFR protein (PDB ID: 4HJO). Finally, compounds 5b, 5d, and 5e followed Lipinski, Ghose, Veber, and Egan rule without deviation.